Tag

Biotech

All articles tagged with #biotech

biotech9 hours ago•18 min saved

NIH Cancer Initiative Sparks 14% Jump in Moderna Shares

Moderna shares surged over 14% on October 9, 2026, after reports that the National Institutes of Health (NIH) will launch a major public-private cancer research initiative in December. The program aims to accelerate treatments for pancreatic, liver, and colorectal cancers, as well as pediatric tumors, leveraging advances in AI and mRNA technology. This move follows recent positive clinical trial results for Moderna’s co-developed melanoma therapy, intismeran, which showed improved outcomes when combined with Merck’s Keytruda.

via Yahoo Finance|

#biotech #cancer-research #moderna

biotech3 days ago•0 min saved

Caribou Biosciences Halts CAR-T Pipeline and Cuts Staff Amid Funding Freeze

Caribou Biosciences is shutting down its clinical pipeline and laying off staff after failing to secure capital for late-stage trials. The company, which developed off-the-shelf cell therapies, is now seeking strategic alternatives like a merger or asset sale. Its stock plummeted following the announcement.

via Fierce Biotech|

#biotech #biotech-funding #car-t-therapy

biotech5 days ago•1 min saved

CSL Secures Co-Development Rights for Alentis Fibrosis Drug in $1.55B Deal

CSL has agreed to pay $355 million upfront and up to $1.2 billion in milestones to co-develop and co-commercialize Alentis Therapeutics' phase 2 fibrosis drug, lixudebart. The deal grants CSL 55% of profits and funding for trials in kidney and liver diseases, including a phase 3 study for antineutrophil cytoplasmic antibodies-associated vasculitis.

via Fierce Biotech|

#alentis-therapeutics #biotech #claudin-1

biotech5 days ago•1 min saved

Genmab’s Rina-S Shows Superior Survival and Safety Profile vs. AbbVie’s Elahere

Genmab’s rinatabart sesutecan (Rina-S) demonstrated a median progression-free survival of 9.5 months in platinum-resistant ovarian cancer, significantly outperforming AbbVie’s Elahere at 5.6 months. While the objective response rate was 45.9%, analysts highlighted superior safety profiles, including no ocular toxicity, and potential for $2 billion in sales.

via Fierce Biotech|

#abbvie #antibody-drug-conjugate #biotech

biotech5 days ago

Mixed Trial Outcomes Force Cancer Vaccine Field to Reassess Scope

Recent mixed results in cancer vaccine trials have forced the biotech industry to reassess the scope of mRNA-based therapies. While a late-stage melanoma trial showed promise, other programs have failed or been halted, raising questions about which cancers can effectively be targeted by this technology.

via STAT|

#biotech #cancer #clinical-trials

biotech5 days ago•1 min saved

Vaxcyte’s 31-valent vaccine hits primary endpoints, sending shares up 57%

Vaxcyte reported positive phase 3 results for its 31-valent pneumococcal vaccine, VAX-31, demonstrating non-inferiority against Pfizer and Merck competitors. The stock surged 57% in pre-market trading, reaching $88.50, as the company prepares for an FDA approval application in early 2028.

via Fierce Biotech|

#biotech #merck #pfizer

biotech5 days ago•0 min saved

Genentech Licenses Alector’s Brain-Penetrant Parkinson’s Drug for $1.27B

Genentech has acquired exclusive global rights to Alector’s preclinical Parkinson’s candidate, AL050, in a deal worth up to $1.27 billion. The agreement includes a $100 million upfront payment and extends Alector’s cash runway to 2029.

via fiercebiotech.com|

#alector #biotech #blood-brain-barrier

biotech9 days ago

Sanofi and Regeneron Rebuild Alliance with $8B Immunology Deal

Sanofi and Regeneron have signed a new collaboration agreement worth up to $8 billion to develop four early-stage immunology assets. The deal includes a $1 billion upfront payment from Sanofi and up to $7 billion in potential milestone payments. This partnership aims to secure future growth for Sanofi as its blockbuster drug, Dupixent, faces patent expiration in 2031. The agreement also resolves a 2024 lawsuit filed by Regeneron against Sanofi over commercialization details. Regeneron will lead research and development for the assets, while Sanofi will handle global commercialization. The most advanced asset, REGN20423, is already in clinical trials for eczema.

via Fierce Biotech|

#biotech #dupixent #immunology

biotech9 days ago•8 min saved

Origin Genomics Founder Argues Gene-Editing Embryos Is a Moral Imperative

Cathy Tie, founder of Origin Genomics, argues that editing human embryos to prevent hereditary diseases is a moral imperative, despite current U.S. bans and safety concerns. While critics warn of eugenics and off-target risks, proponents cite new precise editing tools and patient demand for alternatives to IVF screening.

via WIRED|

#bioethics #biotech #crispr

science-and-technology11 days ago•5 min saved

AI boosts individual output but narrows scientific scope, demanding institutional reform

AI tools increase individual researcher productivity but risk narrowing the overall scope of scientific inquiry. Institutions must shift incentives to reward the creation of new data and support interdisciplinary pivots, rather than optimizing existing datasets.

via Nature|

#academic-incentives #ai-in-science #biotech

biotech11 days ago

Kodiak Sciences Stock Doubles as Zenkuda Matches Eylea in Phase 3 Trial

Kodiak Sciences shares surged 128% after its Phase 3 trial showed its eye drug Zenkuda matched the efficacy of Regeneron’s Eylea for wet age-related macular degeneration. The company plans to file for FDA approval in the fourth quarter of 2026, leveraging an AI-guided dosing strategy that allows longer intervals between injections.

via fiercebiotech.com|

#biotech #eylea #fda-approval

biotech12 days ago•18 min saved

Kodiak Sciences stock triples as Zenkuda matches Eylea in Phase 3 trial

Kodiak Sciences shares surged nearly 178% after its Phase 3 Daybreak trial results showed that both Zenkuda and tabirafusp-ted matched the efficacy of aflibercept (Eylea) for wet age-related macular degeneration. The company plans to file for FDA approval of Zenkuda in the fourth quarter of 2026, citing data that allows for extended dosing intervals.

via Yahoo Finance|

#biotech #fda-approval #kodiak-sciences

biotech12 days ago

Roche Halts Emugrobart Obesity Trial After Failed Interim Analysis

Roche has terminated development of emugrobart, a myostatin-blocking antibody intended to preserve muscle during weight loss, after an interim analysis of its phase 2 Gyminda trial indicated the drug was unlikely to meet its endpoints. The company has returned the asset to its Japanese subsidiary, Chugai, which plans to resume development for spinal muscular atrophy and seek licensing partners. This setback follows earlier failures in muscular dystrophy trials and occurs as Roche expands its obesity portfolio through other deals.

via Fierce Biotech|

#biotech #chugai #emugrobart

biotech12 days ago•0 min saved

Adicet Bio Reports Lupus Remissions in CAR-T Trial, Avoiding Safety Issues Seen in Rivals

Adicet Bio reported that its off-the-shelf CAR-T therapy, prula-cel, induced remission in over half of lupus patients in a Phase 1 trial. The treatment showed a favorable safety profile with no severe inflammatory events, distinguishing it from rival autologous therapies that recently faced trial pauses due to fatalities.

via Fierce Biotech|

#adicet-bio #autoimmune-disease #biotech

biotech12 days ago•19 min saved

Kodiak Sciences Stock Surges 128% on Positive Phase 3 Eye Disease Trial Results

Kodiak Sciences shares jumped 128% after its Phase 3 DAYBREAK trial showed its drug Zenkuda matched the efficacy of aflibercept for wet age-related macular degeneration. The company plans to file for FDA approval in Q4 2026.

via Yahoo Finance|

#amd #biotech #clinical-trials